CoChat

The DOI matches its Crossref record; 113 of the 114 references it cites were found in a registry or an index.

NF-κB: A Double-Edged Sword Controlling Inflammation

Open access
Liu, Danhui, Zhong, Zhenyu, Karin, Michael · 2022 · Biomedicines

Abstract

Inflammation, when properly mounted and precisely calibrated, is a beneficial process that enables the rapid removal of invading pathogens and/or cellular corpses and promotes tissue repair/regeneration to restore homeostasis after injury. Being a paradigm of a rapid response transcription factor, the nuclear factor-kappa B (NF-κB) transcription factor family plays a central role in amplifying inflammation by inducing the expression of inflammatory cytokines and chemokines. Additionally, NF-κB also induces the expression of pro-survival and -proliferative genes responsible for promoting tissue repair and regeneration. Paradoxically, recent studies have suggested that the NF-κB pathway can also exert inhibitory effects on pro-inflammatory cytokine production to temper inflammation. Here, we review our current understanding about the pro- and anti-inflammatory roles of NF-κB and discuss the implication of its dichotomous inflammation-modulating activity in the context of inflammasome activation and tumorigenesis.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3390/biomedicines10061250

Cites

113 of 113 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 NF-κB controls both the gas pedal and brake of the NLRP3 inflammasome. During inflammasome priming, TLR activation results in NF-κB-dependent robust transcriptional upregulation of NLRP3 and de novo synthesis of pro-IL-1β. In parallel, NF-κB activation also induces p62 upregulation, although with slower kinetics. In the inflammasome activation step, various NLRP3 inflammasome activators trigger mitochondrial damage, resulting in the generation of oxidized mtDNA (ox-mtDNA), which is subsequently released from the damaged mitochondria to the cytosol, where it binds to and activates NLRP3. This leads to the assembly of the inflammasome complex, followed by autocleavage and activation of caspase-1, which in turn proteolytically processes pro-IL-1β into its mature and bioactive form, thereby igniting inflammation. Meanwhile, to prevent NLRP3 overactivation, p62 induced upon NF-κB activation promotes the autophagic degradation of the damaged mitochondria, a process also known as mitophagy, and thereby restricts NLRP3 hyperactivation. In summary, NF-κB controls both the gas pedal and brake of NLRP3 inflammasome to generate a well-balanced immune response that focuses on the removal of insults and tissue repair while avoiding immunopathology (the figure was created using BioRender).
Figure 1 NF-κB controls both the gas pedal and brake of the NLRP3 inflammasome. During inflammasome priming, TLR activation results in NF-κB-dependent robust transcriptional upregulation of NLRP3 and de novo synthesis of pro-IL-1β. In parallel, NF-κB activation also induces p62 upregulation, although with slower kinetics. In the inflammasome activation step, various NLRP3 inflammasome activators trigger mitochondrial damage, resulting in the generation of oxidized mtDNA (ox-mtDNA), which is subsequently released from the damaged mitochondria to the cytosol, where it binds to and activates NLRP3. This leads to the assembly of the inflammasome complex, followed by autocleavage and activation of caspase-1, which in turn proteolytically processes pro-IL-1β into its mature and bioactive form, thereby igniting inflammation. Meanwhile, to prevent NLRP3 overactivation, p62 induced upon NF-κB activation promotes the autophagic degradation of the damaged mitochondria, a process also known as mitophagy, and thereby restricts NLRP3 hyperactivation. In summary, NF-κB controls both the gas pedal and brake of NLRP3 inflammasome to generate a well-balanced immune response that focuses on the removal of insults and tissue repair while avoiding immunopathology (the figure was created using BioRender).CC BY · PubMed Central
Figure 2 The NF-κB−NLRP3 inflammasome axis regulates tumorigenesis through modulating the tumor microenvironment. NLRP3 inflammasome-induced IL-1β production promotes MDSCs’ and TAMs’ infiltration, thereby driving breast cancer progression. NLRP3 could also suppress NK-cell and IFN-γ mediated antitumor responses in carcinogen-induced cancers and melanoma. Moreover, NLRP3 signaling drives pancreatic tumorigenesis by inducing tolerogenic T-cell differentiation and adaptive immune suppression. In contrast to these tumor-promoting effects, the NLRP3 inflammasome also suppresses tumorigenesis. For instance, NLRP3 inflammasome-dependent IL-1β production by dendritic cells directs an effective CD8+ T cell response against transplantable tumors. In colitis-associated colorectal cancer, NLRP3 inflammasome-induced IL-18 promotes an epithelial barrier healing process to prevent colorectal cancer progression and metastasis. Furthermore, IL-18 can also promote the tumoricidal activity of NK cells against metastasized colonic tumors and directly induce cancer cell pyroptosis. Lastly, NLRP3 inflammasome-dependent IL-18 downregulates the IL-22-binding protein (IL-22BP), whose production fine tunes IL-22 biological activity to regulate colonic tumorigenesis (the figure was created using BioRender).
Figure 2 The NF-κB−NLRP3 inflammasome axis regulates tumorigenesis through modulating the tumor microenvironment. NLRP3 inflammasome-induced IL-1β production promotes MDSCs’ and TAMs’ infiltration, thereby driving breast cancer progression. NLRP3 could also suppress NK-cell and IFN-γ mediated antitumor responses in carcinogen-induced cancers and melanoma. Moreover, NLRP3 signaling drives pancreatic tumorigenesis by inducing tolerogenic T-cell differentiation and adaptive immune suppression. In contrast to these tumor-promoting effects, the NLRP3 inflammasome also suppresses tumorigenesis. For instance, NLRP3 inflammasome-dependent IL-1β production by dendritic cells directs an effective CD8+ T cell response against transplantable tumors. In colitis-associated colorectal cancer, NLRP3 inflammasome-induced IL-18 promotes an epithelial barrier healing process to prevent colorectal cancer progression and metastasis. Furthermore, IL-18 can also promote the tumoricidal activity of NK cells against metastasized colonic tumors and directly induce cancer cell pyroptosis. Lastly, NLRP3 inflammasome-dependent IL-18 downregulates the IL-22-binding protein (IL-22BP), whose production fine tunes IL-22 biological activity to regulate colonic tumorigenesis (the figure was created using BioRender).CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 114 references

Research works printed but not linked: 2

  1. Tak, 2001, Inhibitor of nuclear factor κB kinase β is a key regulator of synovial inflammation, Arthritis Rheum., 44, 1897, 10.1002/1529-0131(200108)44:8<1897::AID-ART328>3.0.CO;2-4 · DOI
  2. Salim, 2014, Influence of genetic polymorphisms (IL-10/CXCL8/CXCR2/NFkappaB) on the susceptibility of autoimmune rheumatic diseases, Rev. Bras. Reum., 54, 301

Cited by

See all 158

Metadata

Authors
Liu, D., Zhong, Z., & Karin, M.
Affiliations
  • The University of Texas Southwestern Medical Center (US)
  • University of California San Diego (US)
Corresponding author
  • Zhong, Zhenyu
  • Karin, Michael
Venue
Biomedicines
Publisher
MDPI AG
Published
2022-05-27
Volume
10
Issue
6
Pages
1250
ISSN
2227-9059 (ISSN-L)
OpenAlex
W4281657835
Cited by
157
References
114
Citations by year
2026: 57 · 2025: 44 · 2024: 29 · 2023: 19 · 2022: 7
FWCI
2.99
Type
journal article
Language
en
Open access
Locations
  • Biomedicines (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
  • CPRIT New Investigator Recruitment Award (RR180014, R35GM142654, K22AI135074, R37AI043477, R01CA234128, U01AA027681)
  • NIH (RR180014, R35GM142654, K22AI135074, R37AI043477, R01CA234128, U01AA027681)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › NF-κB Signaling Pathways
  • Life Sciences › Immunology and Microbiology › Immunology › Immune Response and Inflammation
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Signaling Pathways in Disease
Keywords
NF-κB, inflammation, anti-inflammatory regulation, inflammatory cytokines, chemokines, tissue repair, tissue regeneration, inflammasome activation, carcinogenesis, homeostasis

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: NF-κB: A Double-Edged Sword Controlling Inflammation. https://app.cochat.ai/papers/10.3390/biomedicines10061250
The paper
Liu, D., Zhong, Z., & Karin, M. (2022). NF-κB: A Double-Edged Sword Controlling Inflammation. Biomedicines. https://doi.org/10.3390/biomedicines10061250

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.